← Eichor
Study identifier: NCT05524090 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

PREOPANC-4 Implementation Program for Locally Advanced Pancreatic Cancer

Condition: Pancreatic Cancer · Locally Advanced Pancreatic Adenocarcinoma · Pancreatic Adenocarcinoma Non-resectable  ·  Sponsor: Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)

PhaseN/A
Planned participants223
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

A prospective, nationwide, implementation program of the international standard of excellence for locally advanced pancreatic cancer (LAPC) care in the Netherlands (2021\[7\]-2030\[6\]), including a multidisciplinary training program by the four leading international expert centers. The PREOPANC-4 project aims a safe and patient-centered implementation of the international standards of excellence for LAPC (surgery) in the Netherlands.

This description comes directly from the study's public registry record.

Talk to the study team

Thomas F Stoop, MD  ·  +316 547 555 11  ·  t.f.stoop@amsterdamUMC.nl

Marc G Besselink, MD, MSc, PhD  ·  +316 16 15 83 45  ·  m.g.besselink@amsterdamUMC.nl

Always discuss trial participation with your own doctor first.

Locations (1)

Amsterdam UMC, locatie AMCAmsterdam, North Holland, NetherlandsRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT05524090